4.1 Review

Estetrol: From Preclinical to Clinical Pharmacology and Advances in the Understanding of the Molecular Mechanism of Action

Journal

DRUGS IN R&D
Volume 23, Issue 2, Pages 77-92

Publisher

SPRINGER INT PUBL AG
DOI: 10.1007/s40268-023-00419-5

Keywords

-

Ask authors/readers for more resources

Estetrol (E4) is a recently described natural estrogen that is produced by the human fetal liver during pregnancy. Its physiological function is still unclear, but it has been approved as a component of a combined oral contraceptive and is being developed for use in menopausal hormone therapy. E4 has shown tissue-specific activity and a more selective pharmacological profile compared to other estrogens, with a low impact on the liver and hemostasis balance. This review summarizes the pharmacological properties of E4 and explores recent advancements in understanding its molecular mechanisms of action.
Estetrol (E4) is the most recently described natural estrogen. It is produced by the human fetal liver during pregnancy and its physiological function remains unclear. E4 is the estrogenic component of a recently approved combined oral contraceptive. It is also in development for use as menopausal hormone therapy. In the context of these developments, the pharmacological activity of E4, alone or in combination with a progestin, has been extensively characterized in preclinical models as well as in clinical studies in women of reproductive age and postmenopausal women. Despite the clinical benefits, the use of oral estrogens for contraception or menopause is also associated with unwanted effects, such as an increased risk of breast cancer and thromboembolic events, due to their impact on non-target tissues. Preclinical and clinical data for E4 point to a tissue-specific activity and a more selective pharmacological profile compared with other estrogens, including a low impact on the liver and hemostasis balance. This review summarizes the characterization of the pharmacological properties of E4 as well as recent advances made in the understanding of the molecular mechanisms of action driving its activity. How the unique mode of action and the different metabolism of E4 might support its favorable benefit-risk ratio is also discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available